Despite promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable opposition from PBMs. Such companies are typically creating obstacles to coverage, such as significant expense criteria and PA that limit user access. Industry indicate that these coverage obstacles pose